Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 3
2009 6
2010 5
2011 5
2012 5
2013 5
2014 4
2015 4
2016 7
2017 3
2018 4
2019 5
2020 5
2021 1
2022 2
2024 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination t …
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization funct …
A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery.
Hill KD, Maharaj AR, Li JS, Thompson E, Barker PCA, Hornik CP. Hill KD, et al. Pediatr Crit Care Med. 2020 Sep;21(9):e795-e803. doi: 10.1097/PCC.0000000000002410. Pediatr Crit Care Med. 2020. PMID: 32639468 Free PMC article. Clinical Trial.
CONCLUSIONS: Ambrisentan clearance is reduced following Fontan surgery, perhaps reflecting abnormal hepatic metabolism in this population. The observed safety profile appears favorable and hemodynamic effects of ambrisentan may be beneficial for Fontan patients....
CONCLUSIONS: Ambrisentan clearance is reduced following Fontan surgery, perhaps reflecting abnormal hepatic metabolism in this popula …
Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial.
Weatherald J, Thakrar MV, Varughese RA, Kularatne M, Liu J, Harper L, Kiamanesh O, Fine N, Orlikow E, Nwaroh C, Thornton C, Swiston J, Kolkman L, Brunner NW, Helmersen D, Hirani N. Weatherald J, et al. J Heart Lung Transplant. 2022 May;41(5):563-567. doi: 10.1016/j.healun.2022.01.002. Epub 2022 Jan 10. J Heart Lung Transplant. 2022. PMID: 35090807 Clinical Trial.
METHODS: We performed a prospective, single-arm, open-label trial of riociguat, and ambrisentan for incident PAH patients in functional class III. The primary endpoint was pulmonary vascular resistance (PVR) at 4-months. ...Six patients discontinued riociguat and 8 discont …
METHODS: We performed a prospective, single-arm, open-label trial of riociguat, and ambrisentan for incident PAH patients in function …
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS. Preston IR, et al. J Heart Lung Transplant. 2020 May;39(5):464-472. doi: 10.1016/j.healun.2019.12.008. Epub 2020 Jan 21. J Heart Lung Transplant. 2020. PMID: 32008947 Clinical Trial.
BACKGROUND: Ambrisentan has shown effectiveness in the treatment of Group 1 pulmonary arterial hypertension (PAH). ...One episode of leg edema resulted into the permanent discontinuation of ambrisentan. CONCLUSIONS: Ambrisentan monotherapy in PoPH improves he …
BACKGROUND: Ambrisentan has shown effectiveness in the treatment of Group 1 pulmonary arterial hypertension (PAH). ...One episode of …
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, Gillies H, Tislow J, Oudiz RJ. Shapiro S, et al. Respir Med. 2017 May;126:84-92. doi: 10.1016/j.rmed.2017.03.025. Epub 2017 Mar 29. Respir Med. 2017. PMID: 28427554 Free article. Clinical Trial.
While recent data supports the initial combination of ambrisentan (a selective ERA) and tadalafil (a PDE5i) in functional class II or III patients, there is no published data describing the safety and efficacy of ambrisentan when added to patients currently receivin …
While recent data supports the initial combination of ambrisentan (a selective ERA) and tadalafil (a PDE5i) in functional class II or …
Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation.
Allan JM, Fox BM, Kasztan M, Kelly GC, Molina PA, King MA, Colson J, Wells L, Bowman L, Blackburn M, Kutlar A, Harris RA, Pollock DM, Pollock JS. Allan JM, et al. Clin Sci (Lond). 2024 Dec 4;138(23):1505-1520. doi: 10.1042/CS20240625. Clin Sci (Lond). 2024. PMID: 39526571 Clinical Trial.
Significantly enhanced vasoconstriction in aortic and carotid arterial segments were observed from HbSS mice compared with HbAA mice. Treatment with ambrisentan, a selective ETA receptor antagonist, and a ROS scavenger normalized the aortic vasoconstrictive response in HbS …
Significantly enhanced vasoconstriction in aortic and carotid arterial segments were observed from HbSS mice compared with HbAA mice. Treatm …
Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.
Schroeder T, Piantadosi CA, Natoli MJ, Autmizguine J, Cohen-Wolkowieczs M, Hamilton KL, Bell C, Klawitter J, Christians U, Irwin DC, Noveck RJ. Schroeder T, et al. Clin Pharmacol Ther. 2018 May;103(5):888-898. doi: 10.1002/cpt.860. Epub 2017 Oct 17. Clin Pharmacol Ther. 2018. PMID: 28857147 Free PMC article. Clinical Trial.

Aminophylline alleviated hypoxia-induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% >placebo). Single-dose ambrisentan increased

…

Aminophylline alleviated hypoxia-induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05

…
Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M, Jing ZC, Li Y, Huo Y, Yu Z, Zhang G, Zhu P, Liu J, Ji Q, Wu B, Zhong J, Wang P, Zhu W, Zeng X. Li M, et al. BMC Cardiovasc Disord. 2020 Jul 17;20(1):339. doi: 10.1186/s12872-020-01591-1. BMC Cardiovasc Disord. 2020. PMID: 32680480 Free PMC article. Clinical Trial.
BACKGROUND: The efficacy and safety of ambrisentan has been previously evaluated in Chinese patients with pulmonary arterial hypertension (PAH). This post-hoc analysis assessed the efficacy and safety of ambrisentan in a subgroup of connective tissue disease (CTD) p …
BACKGROUND: The efficacy and safety of ambrisentan has been previously evaluated in Chinese patients with pulmonary arterial hyperten …
Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
Blalock SE, Matulevicius S, Mitchell LC, Reimold S, Warner J, Peshock R, Torres F, Chin KM. Blalock SE, et al. J Card Fail. 2010 Feb;16(2):121-7. doi: 10.1016/j.cardfail.2009.09.008. Epub 2009 Nov 20. J Card Fail. 2010. PMID: 20142023 Free PMC article. Clinical Trial.
BACKGROUND: This study evaluated long-term outcomes in patients with pulmonary arterial hypertension (PAH) undergoing treatment with ambrisentan monotherapy, a selective oral endothelin-1 receptor antagonist. METHODS AND RESULTS: Patients who participated in the Ambrise …
BACKGROUND: This study evaluated long-term outcomes in patients with pulmonary arterial hypertension (PAH) undergoing treatment with ambr …
Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Hatano M, Abe K, Koike G, Takahashi T, Tunmer G, Kiely DG. Hatano M, et al. Int Heart J. 2022;63(1):99-105. doi: 10.1536/ihj.21-497. Int Heart J. 2022. PMID: 35095084 Free article. Clinical Trial.
The AMBITION study (NCT01178073) provided the first long-term clinical evidence for initial combination therapy with ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH). Nevertheless, predictors of treatment response were not assessed.To identi …
The AMBITION study (NCT01178073) provided the first long-term clinical evidence for initial combination therapy with ambrisentan and …
59 results